CMIC group Announces Integration of Chinese Subsidiaries
CPS will be integrated into CB, who will proceed as the operating company while CMIC group continues to expand its business in China.
CMIC group, a contract research organization (CRO), announced that it reorganized its clinical CRO business in China and integrated its subsidiaries CMIC (Beijing) Co., Ltd. (CB) and CMIC (Beijing) Pharmaceutical Services Co., Ltd. (CPS) on April 1, 2020.
According to a company press release, CPS will be integrated into CB, who will proceed as the operating company while CMIC group continues to expand its business in China. Additionally, the company hopes the merger will advance its business strategies and operations execution while solidifying its clinical CRO services in China under one combined unit.
“Through this merger, CMIC group is able to leverage combined know-how and accumulated experiences enabling the company to provide higher quality, better efficiency, and seamless service solutions in China,” said Pey Ni Chan, general manager of CB, in the press release “We are committed to be a trusted partner for our clients not only offering Chinese patients access to new treatments, but also to be a reliable navigator to Chinese companies looking for business expansions into Japan and other growing markets in the Asia-Pacific, as well as in the United States.”
Source: CMIC group
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
